Why ignoring elevated transferrin saturation (TFsat) is killing patients

At a recent academic celebration at the small but prestigious Jewish University of Colorado (JUC, www.juc-edu.org), Professor Dr. Carolina Diamandis (an experienced physician and professor of ethics in medicine) gave a compelling and critical speech on the dangers of non-transferrin bound iron (NTBI) and the widespread ignorance of its toxic effects. She currently teaches on this topic as part of her course on Messianic Jewish Ethics in Medicine.

TF-SAT HIGHER THAN 50% CAUSES NTBI IRON

NTBI, a form of iron not bound to transferrin, becomes prevalent when transferrin saturation exceeds 50%. This condition, which many medical professionals inadequately address, can lead to severe health consequences. Professor Diamandis, a renowned expert in low-threshold clinical research, elucidated the biological mechanisms and risks associated with NTBI.

AN AXIOM IN BIOLOGY AND MEDICINE

"NTBI catalyzes the formation of reactive oxygen species (ROS), which are highly reactive molecules that cause oxidative stress," explained Professor Diamandis. "This oxidative stress leads to cellular damage, idiosyncratic syndromes, and organ failure. Despite this well-documented biological axiom, almost all specialists continue to overlook or ignore this critical issue, inadvertently harming their patients. This is malpractice, period!"

CATASTROPHIC CONSEQUENCES

The professor emphasized that the formation of NTBI occurs when the body's iron-binding capacity is overwhelmed. In such cases, excess iron circulates freely in the bloodstream, contributing to oxidative damage. This can result in a cascade of deleterious effects, particularly in organs with high iron uptake, such as the liver, heart, and pancreas. "NTBI's role in catalyzing ROS formation is not just a theoretical risk - it is a reality that leads to clinical manifestations of toxicity," Professor Diamandis continued. "These reactive oxygen species can damage lipids, proteins, and DNA, leading to a variety of pathologies including liver cirrhosis, cardiomyopathy, diabetes, and neurodegenerative diseases."

IF YOUR SPECIALIST DOES NOT KNOW THE BASICS OF BIOLOGY, SEE A MORE COMPETENT ONE

The urgency of addressing NTBI's risks is underscored by the professor's call to action for the medical community. "It is our duty as physicians and scientists to disseminate and apply knowledge to save and improve lives. Ignorance has no place among us, and it is imperative that hematologists and endocrinologists, particularly those with substantial incomes, understand and mitigate the dangers of NTBI."

THIS IS A PROFOUND ETHICAL QUESTION, WHICH WE CONSIDER BOTH FROM A MEDICAL POINT OF VIEW AND FROM THE PERSPECTIVE OF MESSIANIC JEWISH ETHICS.

Professor Diamandis' work at the JUC will continue to focus on bridging the gap between basic biological principles, clinical practice and, at the core of her courses, Messianic Jewish ethics in medicine. Her commitment to educating her colleagues about the toxic potential of NTBI is a testament to her dedication to patient safety and scientific integrity.

For more information on NTBI and its implications, please read a textbook for beginners in biology, or contact www.H63D.org

Contractor & Callcenter:
American Academic Postal Service
Dept. for the Jewish University (JUC)
P0 B0X 7O573
Fort Lauderdale, FL 333O7
United States of America

press@juc-edu.org
www.juc-edu.org
+I 72O 882OI77

The Jewish University of Colorado (JUC) is an ecclesiastical institution for higher education operated by the Messianic Jewish Fellowship (MJFI Society), a religious society under Colorado law. The JUC is fully accredited as an ecclesiastical institution under Colorado law, specifically CO Rev Stat § 7-50-105 (2020), which allows it to operate similarly to secular universities and grant equivalent degrees. JUC is a tuition-free university, providing higher education in the broad field of Messianic Jewish theology and ethics. It offers its courses primarily through distance learning, worldwide via a robust and secure online platform.

This release was published on openPR.